CN117797040B - Whitening nanoemulsion containing 4-butylresorcinol and preparation method thereof - Google Patents
Whitening nanoemulsion containing 4-butylresorcinol and preparation method thereof Download PDFInfo
- Publication number
- CN117797040B CN117797040B CN202311871201.4A CN202311871201A CN117797040B CN 117797040 B CN117797040 B CN 117797040B CN 202311871201 A CN202311871201 A CN 202311871201A CN 117797040 B CN117797040 B CN 117797040B
- Authority
- CN
- China
- Prior art keywords
- extract
- butylresorcinol
- nanoemulsion
- whitening
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 74
- 230000002087 whitening effect Effects 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 16
- 239000012074 organic phase Substances 0.000 claims abstract description 16
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 claims abstract description 13
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 claims abstract description 13
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 13
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 13
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000012071 phase Substances 0.000 claims abstract description 12
- HIXYEIRACBUSON-FJXQXJEOSA-N (2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;hydrochloride Chemical compound Cl.NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 HIXYEIRACBUSON-FJXQXJEOSA-N 0.000 claims abstract description 9
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims abstract description 9
- 108010087806 Carnosine Proteins 0.000 claims abstract description 9
- 229940070763 carnosine hydrochloride Drugs 0.000 claims abstract description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940082500 cetostearyl alcohol Drugs 0.000 claims abstract description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000502 poloxamer Drugs 0.000 claims abstract description 8
- 229920001983 poloxamer Polymers 0.000 claims abstract description 8
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 239000003755 preservative agent Substances 0.000 claims abstract description 3
- 230000002335 preservative effect Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- 239000000243 solution Substances 0.000 claims description 58
- 239000000284 extract Substances 0.000 claims description 57
- 241000220225 Malus Species 0.000 claims description 41
- 239000006228 supernatant Substances 0.000 claims description 16
- 235000013405 beer Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 239000004359 castor oil Substances 0.000 claims description 9
- 235000019438 castor oil Nutrition 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002137 ultrasound extraction Methods 0.000 claims description 7
- 235000021016 apples Nutrition 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 230000009849 deactivation Effects 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 229940106579 hops extract Drugs 0.000 claims 2
- 239000001906 humulus lupulus l. absolute Substances 0.000 claims 2
- 244000116484 Inula helenium Species 0.000 claims 1
- 235000002598 Inula helenium Nutrition 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 22
- 230000008099 melanin synthesis Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 58
- 238000012360 testing method Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 230000001186 cumulative effect Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 230000035699 permeability Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 231100000245 skin permeability Toxicity 0.000 description 8
- 208000003351 Melanosis Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 230000036564 melanin content Effects 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 238000002834 transmittance Methods 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- -1 compound isopropyl palmitate Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- RMFGNMMNUZWCRZ-UHFFFAOYSA-N Humulone Natural products CC(C)CC(=O)C1=C(O)C(O)(CC=C(C)C)C(O)=C(CC=C(C)C)C1=O RMFGNMMNUZWCRZ-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- OLHLJBVALXTBSQ-UHFFFAOYSA-N Lupulone Natural products CC(C)CC(=O)C1C(=O)C(CC=C(C)C)C(=O)C(CC=C(C)C)(CC=C(C)C)C1=O OLHLJBVALXTBSQ-UHFFFAOYSA-N 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPVSVIXDXMNGGN-UHFFFAOYSA-N beta-bitter acid Natural products CC(C)CC(=O)C1=C(O)C(CC=C(C)C)(CC=C(C)C)C(=O)C(CC=C(C)C)=C1O WPVSVIXDXMNGGN-UHFFFAOYSA-N 0.000 description 1
- 239000003157 biological pigment Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- VMSLCPKYRPDHLN-NRFANRHFSA-N humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@@](O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-NRFANRHFSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- LSDULPZJLTZEFD-UHFFFAOYSA-N lupulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(CC=C(C)C)(CC=C(C)C)C1=O LSDULPZJLTZEFD-UHFFFAOYSA-N 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a whitening nanoemulsion containing 4-butylresorcinol and a preparation method thereof, and aims to provide a whitening nanoemulsion with the effects of inhibiting melanin synthesis and accelerating melanin metabolic degradation; the technical scheme comprises the following components in percentage by mass: 13.08 to 29.12 percent of active factor, 4 to 40.5 percent of emulsifier phase, 2.2 to 41.8 percent of organic phase, 0.1 to 1 percent of preservative and a proper amount of water; the active factors comprise 4-butyl resorcinol, nonapeptide-1, decarboxylated carnosine hydrochloride, 3-o-ethyl ascorbic acid and tocopheryl acetate; the emulsifier comprises poloxamer, polyvinylpyrrolidone and cetostearyl alcohol polyether-20; belongs to the technical field of cosmetics.
Description
Technical Field
The invention discloses a whitening nanoemulsion, in particular a 4-butylresorcinol-containing whitening nanoemulsion, and also discloses a preparation method of the whitening nanoemulsion, belonging to the technical field of cosmetics.
Background
With the development of social economy and the improvement of living standard of people, the pursuit of beauty has become an important part of people's daily life. As the whitening effect is more and more sought by the aesthetic concept of "whitening, more and more loving people, especially many women, are also pursuing, various whitening products are becoming hot spots of research.
Medical research shows that the difference of the skin color of a human body mainly depends on the content of melanin in basal layers of the skin, wherein the melanin is black or brown biological pigment generated by melanocytes of the skin, is mainly generated by the melanocytes in the skin, is transferred to keratinocytes of epidermis of the skin, and is finally presented on the skin.
Tyrosine in melanocytes is hydroxylated to dopa under the action of tyrosinase, dopa is oxidized to dopa quinone under the action of tyrosinase, and melanin particles are formed, and melanin is gradually transferred from cells to basal layers and precipitated in the basal layers, so that pigmentation is caused. The more melanin is produced, the darker the skin; on the contrary, the more fair the skin is.
In addition, melanin production is affected by external environmental factors and in-vivo metabolic disorders, such as ultraviolet rays, air pollution, in-vivo oxidation and oxidation resistance system imbalance, microecological balance, abnormal trace element content of organisms and the like, besides genetic factors.
Therefore, skin whitening is mainly required to achieve a whitening effect by suppressing the generation and deposition of melanin in the basal layer, and improving the brightness of the skin. Whitening cosmetics can be classified into the following categories according to the action mechanism of whitening components: (1) Reducing melanin production by inhibiting the activity of tyrosinase and other enzymes; (2) Reducing melanin deposition on the top layer of the skin by inhibiting transfer of melanosomes; (3) reducing melanin production by scavenging free radicals; (4) By promoting metabolism of the stratum corneum, melanin excretion is accelerated.
4-Butyl resorcinol is a novel antioxidant capable of inhibiting browning, is the strongest tyrosinase inhibitor discovered so far, and has super-strong whitening effect: in vitro experiments also prove that the whitening effect is 500 times stronger than that of arbutin, and can effectively inhibit melanin synthesis, melanin pigmentation, chloasma and freckle; however, 4-butyl resorcinol has certain irritation, has the phenomenon of intolerance to skin, and is easy to cause allergic phenomena such as redness, swelling and pain and the like of the skin; in addition, 4-butylresorcinol is poorly soluble in water, is easily oxidized and is easily discolored, thus limiting its use.
CN202310858296.X discloses a whitening 4-butyl resorcinol gel bead and a preparation method thereof, wherein the scheme is prepared from the following raw materials in percentage by mass: agarose 0-10%, agar 0-10%, xanthan gum 0-5%, guar gum 0-5%, sodium alginate 0-20%, calcium chloride 0-20%, water 10-98%, 4-butylresorcinol 0.001-10%, other oil-soluble functional components 0-10%, other water-soluble functional substances 0-10%, emulsifying agent 5-60%, auxiliary emulsifying agent 1-40% and oily substances with moisturizing and sliding effects 0-50%, wherein the weight percentages of the components are the weight percentages of the whitening 4-butylresorcinol gel beads. 0-10% of other oil-soluble functional components including 0-10% of 3-o-ethyl ascorbic acid and 0-10% of glycyrrhetinic acid; other water-soluble functional components comprise 0-10% of nicotinamide and 0-10% of tranexamic acid. The emulsifier comprises 800 to 40 percent of tween, 400 to 40 percent of tween, 800 to 40 percent of span, 200 to 40 percent of span, 0 to 50 percent of PEG-40 hydrogenated castor oil, 0 to 50 percent of polyglycerol-10 myristate, 0 to 40 percent of polyglycerol-6 caprylate and 0 to 20 percent of poloxamer. The auxiliary emulsifier comprises 0-30% of propylene glycol, 0-30% of 1, 2-hexanediol, 0-30% of 1, 2-pentanediol, 0-45% of ethoxydiglycol and 0-30% of n-butanol. The oily substances with the moisturizing and sliding effects comprise 0-20% of caprylic triglyceride, 0-20% of isopropyl palmitate, 0-20% of tocopheryl acetate and 0-20% of ceramide.
Therefore, development of a composition for inhibiting melanin synthesis and accelerating melanin metabolism and degradation is particularly necessary.
Disclosure of Invention
In view of the above-mentioned shortcomings, the present invention aims to provide a whitening nanoemulsion with effects of inhibiting melanin synthesis and accelerating melanin metabolic degradation; the whitening nanoemulsion system is stable, is not easy to oxidize, has small irritation to skin and is easy to be absorbed by skin.
The invention also discloses a preparation method of the whitening nanoemulsion.
For this purpose, the first technical solution provided by the present invention is as follows:
The whitening nanoemulsion containing 4-butylresorcinol comprises the following components in percentage by mass: 13.08 to 29.12 percent of active factor, 4 to 40.5 percent of emulsifier phase, 2.2 to 41.8 percent of organic phase, 0.1 to 1 percent of preservative and a proper amount of water;
The active factors comprise 4-butyl resorcinol, nonapeptide-1, decarboxylated carnosine hydrochloride, 3-o-ethyl ascorbic acid and tocopheryl acetate;
The emulsifier comprises poloxamer, polyvinylpyrrolidone and cetostearyl alcohol polyether-20;
Furthermore, the active factors of the whitening nanoemulsion containing 4-butylresorcinol also comprise costustoot extract, hop extract and apple extract.
Further, the weight ratio of the 4-butylresorcinol, the nonapeptide-1, the decarboxylated carnosine hydrochloride, the 3-o-ethyl ascorbic acid and the tocopheryl acetate is as follows: 4-8:0.08-0.12:4-8:4-8:1-5.
Further, the whitening nanoemulsion containing 4-butylresorcinol, wherein the mass ratio of the 4-butylresorcinol, the nonapeptide-1, the decarboxylated carnosine hydrochloride, the 3-o-ethyl ascorbic acid, the tocopheryl acetate, the costustoot extract, the hop extract and the apple extract is as follows: 4-8:0.08-0.12:4-8:4-8:1-5:2-3:1-2:3-5.
Further, the whitening nanoemulsion containing 4-butylresorcinol, wherein the emulsifier further comprises at least one of cetostearyl alcohol polyether-20, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil and acrylic acid (esters) or C10-30 alkanol acrylate crosslinked polymer.
Further, the weight ratio of the poloxamer to the polyvinylpyrrolidone in the whitening nanoemulsion containing 4-butylresorcinol is 1-10:1-10:2-3.
Further, the whitening nanoemulsion containing 4-butylresorcinol is characterized in that the organic phase consists of isopropyl palmitate, 1, 2-hexanediol, 1, 2-pentanediol and ethoxydiglycol according to the mass ratio of 1-10:1-10.
Further, the whitening nanoemulsion containing 4-butylresorcinol is prepared by the following method of the hop extract:
(1) Collecting hops, naturally drying, crushing, and sieving with a 20-40 mesh sieve to obtain beer pollen;
(2) Adding ethanol with the mass concentration of 50-70% into beer pollen according to the volume ratio of 6-8:1, soaking the beer pollen for 30-50 minutes, ultrasonically extracting for 15-30 minutes at the frequency of 40-60 kHz and the power of 150-300W and the temperature of 40-55 ℃, filtering the extracting solution,
(3) Adding ethanol solution with the mass concentration of 50-70% into filter residues again according to the volume ratio of ethanol to beer pollen of 3-5:1, and performing ultrasonic extraction for 10-20 min at the frequency of 40-60 kHz and the power of 150-300W at the temperature of 40-50 ℃; filtering to obtain a second extracting solution, combining the extracting solutions, evaporating and concentrating at the temperature of between 30 and 50kPa and between 35 and 45 ℃ to recover ethanol to obtain an extract primary extract;
(4) Dissolving the extract in an aqueous solution with the mass concentration of 2t% of ethanol, carrying out component enrichment and separation by adopting AB-8 type macroporous adsorption resin, eluting with 20% of ethanol, and then eluting with 70% of ethanol;
(5) Collecting 70% ethanol eluate, and concentrating under reduced pressure of 30kPa to obtain 70% ethanol-eluted flos Lupuli extract;
(6) The hop extract is obtained at the temperature of between 50 ℃ below zero and 30 ℃ below zero for 18 to 20 hours.
Further, the whitening nanoemulsion containing 4-butylresorcinol is prepared from the apple extract by the following method:
1) Selecting fresh apples, cleaning, removing seeds, and crushing the apples to obtain apple paste;
2) Adding 0.1-0.25% of cellulase and 0.2-0.5% of pectase into the apple paste according to the mass of the apple paste, adding 50wt% of ethanol which is 20 times of the mass of the apple paste, adding citric acid to adjust the PH to 5.5-6.0, carrying out enzymolysis for 1-2 h at 50-60 ℃, and then inactivating enzyme in boiling water for 20-30 min;
3) Placing the substances after enzyme deactivation into an ultrasonic extractor, performing ultrasonic treatment at 600W and 50-55 ℃ for 15-20 min, centrifuging at 5000rpm for 12-20 min, centrifuging the extracting solution, and collecting supernatant;
4) Adding 50wt% ethanol with 20 times of the volume of the filter residue into the filter residue, placing into an ultrasonic extractor, performing ultrasonic treatment at 600W and 50-55 ℃ for 15-20 min, centrifuging at 4000rpm for 12-20 min, centrifuging the extracting solution, and collecting supernatant;
5) Combining the supernatant collected in the step 4) and the step 5), concentrating the supernatant in a vacuum rotary evaporator for 1-2 hours until no liquid is evaporated, and freeze-drying the concentrated supernatant at 20Kpa and-25 ℃ for 24-48 hours to obtain an apple crude extract;
6) Dissolving the apple crude extract in distilled water, stirring to dissolve completely, pre-removing impurities with 0.45 μm organic phase microfiltration membrane, collecting filtrate, ultrafiltering the filtrate with ultrafiltration membrane with molecular cut-off of 2kDa at normal temperature and 0.1MPa to obtain ultrafiltrate, and freeze-drying the ultrafiltrate at-25deg.C for 24-48 hr to obtain apple extract.
The second technical scheme provided by the invention is that the preparation method of the whitening nanoemulsion containing 4-butylresorcinol sequentially comprises the following steps:
1) Weighing each substance;
2) Mixing the weighed organic phases in the step 1), heating to 50 ℃, adding 4-butyl resorcinol, tocopheryl acetate and 3-o-ethyl ascorbic acid, and mixing; adding each component of the emulsifier phase, stirring and dissolving;
3) And adding the rest components into the water phase for dissolution, heating the water phase to 50 ℃ after dissolution, slowly adding the organic phase while stirring at the maintained temperature, and stirring until the organic phase is uniform and transparent.
The final technical scheme of the application is the application of the whitening nanoemulsion containing 4-butylresorcinol as an additive for preparing cosmetics.
Compared with the prior art, the technical scheme provided by the invention has the following technical advantages:
1. according to the technical scheme provided by the invention, the 4-butyl resorcinol whitening nanoemulsion is prepared by mutually composing poloxamer, polyvinylpyrrolidone and an organic phase, so that the problem of water solubility of the 4-butyl resorcinol is effectively solved, and the problem of difficult compatibility with other components is solved; the prepared 4-butyl resorcinol whitening nanoemulsion is stable in property, not easy to oxidize, small in skin irritation and easy to absorb.
2. According to the technical scheme provided by the application, poloxamer is adopted as a nonionic surfactant, and the compound polyvinylpyrrolidone improves the solubility and biocompatibility, effectively prolongs the permeation and residence time of the functional components, increases the skin care effect of the functional components, and reduces the irritation of the components such as 4-butylresorcinol and the like to the skin; the stability and the permeability of the cetostearyl alcohol polyether-20, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil and acrylic acid (esters)/C10-30 alkanol acrylate crosslinked polymer provided by the application are further improved by compounding the cetostearyl alcohol polyether-20, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil and acrylic acid (esters) and C10-30 alkanol acrylate crosslinked polymer; the compound isopropyl palmitate, 1, 2-hexanediol, 1, 2-pentanediol and ethoxydiglycol further reduce the oil-water interfacial tension, increase the solubility of the emulsifier, and enable the emulsion to form smaller liquid drops, thereby improving the stability of the nano emulsion system.
3. The whitening active factors provided by the technical scheme comprise 4-butylresorcinol, nonapeptide-1, decarboxylated carnosine hydrochloride, 3-o-ethyl ascorbic acid and tocopheryl acetate, so that the whitening active factors are easy to permeate into the muscle base, inhibit the activity of tyrosinase, prevent melanin from generating and solve color spots at multiple angles; can be used as a contrast agent of melanocyte stimulating hormone, and can be combined with MC1 receptor in a competition way by compounding with nonapeptide-1 to prevent tyrosinase from being further activated to generate melanin; the compound decarboxylated carnosine hydrochloride can effectively capture hydroxyl free radicals, elemental oxygen and hydrogen peroxide free radicals, so that the purpose of scavenging the free radicals is achieved, the oxidation of liposome is inhibited, and cell membranes can be stably protected; inhibit glycosylation of structural proteins, and protect collagen and elastin. The compound 3-o-ethyl ascorbic acid and the tocopheryl acetate lead the active components to be easy to be used by skin, directly participate in the synthesis of collagen after penetrating through the stratum corneum to reach the dermis, restore the activity of skin cells and increase the collagen, thereby leading the skin to become full and elastic and leading the skin to be fine and smooth; has strong antibacterial and antiinflammatory effects, and can further reduce irritation of other components to skin.
4. The whitening activity provided by the invention also comprises costustoot extract, hop extract and apple extract, and the plant extract contains rich flavonoids, vitamins, minerals, polyphenols, humulone, lupulone and the like, and can further effectively remove free radicals in skin such as DPPH free radicals, superoxide anions and the like by mixing with 4-butylresorcinol, nonapeptide-1, decarboxylated carnosine hydrochloride, 3-o-ethyl ascorbic acid and tocopheryl acetate, thereby reducing oxidative stress, protecting cells from oxidative damage, environmental pollution and ultraviolet injury, promoting the renewal of skin cells, improving the elasticity and compactness of skin, reducing the generation of wrinkles and color spots, improving skin color darkness and delaying skin aging; and inhibit the generation of various inflammatory factors, reduce skin inflammatory reaction, relieve skin redness and swelling, pruritus and other symptoms, and improve acne, sensitive skin problems and the like; meanwhile, the moisture content of the skin can be improved, the evaporation of the skin moisture can be inhibited, the moisture retention capacity of the skin can be improved, and the elasticity and luster of the skin can be improved.
5. The hop extract provided by the invention is subjected to ultrasonic extraction and then is subjected to macroporous resin adsorption purification, the apple extract is subjected to ultrasonic extraction and ultrafiltration purification after enzymolysis, the content and purity of active ingredients such as flavonoids, vitamins, minerals and polyphenols are high, and melanin generation is inhibited by a multichannel target spot, so that color spots are solved at multiple angles; and effectively repairing skin barrier, moisturizing, anti-inflammatory, reducing skin stress reaction and relieving skin discomfort.
Drawings
FIG. 1 is a particle size distribution chart of example 1
FIG. 2 is a particle size distribution chart of example 8
FIG. 3 is a TEM image of example 9 after addition of emulsion essence
FIG. 4 is a TEM image of example 10 after addition of emulsion essence
FIG. 5 is a TEM image of example 11 after addition of emulsion essence
FIG. 6 shows the skin condition before the start of the experiment
FIG. 7 shows the skin condition after the end of the experiment (48 h)
FIG. 8 is a statistical histogram of data at 32℃and 37℃for example 1 (4-butylresorcinol nanoemulsion group, NE);
FIG. 9 is a statistical histogram of data at 32℃and 37℃for the 4-butylresorcinol solution group;
Detailed Description
The technical scheme of the invention is further described in detail below with reference to the specific embodiments.
The whitening nanoemulsion containing 4-butylresorcinol provided in the application of example 1 to example 14 comprises the following components:
table 1 examples 1 to 7
Table 2 examples 8 to 14
The costustoot extracts described in examples 1 to 14 were prepared by the following method: pulverizing radix aucklandiae decoction pieces to below 100 mesh, adding 4 equivalent 60% ethanol solution, ultrasonic extracting at room temperature for 1 hr, removing ethanol phase by rotary evaporation, filtering with microporous membrane, and lyophilizing to obtain extract.
The hop extracts described in examples 1 to 14 were prepared by the following method:
(1) Collecting hops, naturally drying, crushing, and sieving with a 20-40 mesh sieve to obtain beer pollen;
(2) Adding ethanol with the mass concentration of 50-70% into beer pollen according to the volume ratio of 6-8:1, soaking the beer pollen for 30-50 minutes, ultrasonically extracting for 15-30 minutes at the frequency of 40-60 kHz and the power of 150-300W and the temperature of 40-55 ℃, filtering the extracting solution,
(3) Adding ethanol solution with the mass concentration of 50-70% into filter residues again according to the volume ratio of ethanol to beer pollen of 3-5:1, and performing ultrasonic extraction for 10-20 min at the frequency of 40-60 kHz and the power of 150-300W at the temperature of 40-50 ℃; filtering to obtain a second extracting solution, combining the extracting solutions, evaporating and concentrating at the temperature of between 30 and 50kPa and between 35 and 45 ℃ to recover ethanol to obtain an extract primary extract;
(4) Dissolving the extract in an aqueous solution with the mass concentration of 2t% of ethanol, carrying out component enrichment and separation by adopting AB-8 type macroporous adsorption resin, eluting with 20% of ethanol, and then eluting with 70% of ethanol;
(5) Collecting 70% ethanol eluate, and concentrating under reduced pressure of 30kPa to obtain 70% ethanol-eluted flos Lupuli extract;
(6) The hop extract is obtained at the temperature of between 50 ℃ below zero and 30 ℃ below zero for 18 to 20 hours.
The apple extracts described in examples 1 to 14 were prepared by the following method:
1) Selecting fresh apples, cleaning, removing seeds, and crushing the apples to obtain apple paste;
2) Adding 0.1% -0.25% (preferably 0.2%) of cellulase and 0.2% -0.5% (preferably 0.3%) of pectase into the apple paste according to the mass of the apple paste, adding 50wt% of ethanol which is 20 times of the mass of the apple paste, adding citric acid to adjust the PH to 5.5-6.0, carrying out enzymolysis at 50-60 ℃ (preferably 55 ℃) for 1-2 hours (preferably 1.5 hours), and then inactivating enzyme in boiling water for 20-30 minutes;
3) Placing the materials after enzyme deactivation into an ultrasonic extractor, performing ultrasonic treatment at 600W and 50-55 ℃ (preferably 55 ℃) for 15-20 min (preferably 20 min), centrifuging at 5000rpm for 12-20 min, centrifuging the extracting solution, and collecting supernatant;
4) Adding 50wt% ethanol which is 20 times the volume of the filter residue into the filter residue, placing into an ultrasonic extractor, performing ultrasonic treatment at 600W and 50-55 ℃ and preferably 55 ℃ for 15-20 min (preferably 20 min), centrifuging at 4000rpm for 12-20 min, centrifuging the extracting solution, and collecting supernatant;
5) Combining the supernatant collected in the step 4) and the step 5), concentrating the supernatant in a vacuum rotary evaporator for 1-2h (preferably 1.5 h) until no liquid is distilled out, and freeze-drying the concentrated supernatant at 20Kpa and-25 ℃ for 24-48 h (preferably 36 h) to obtain an apple crude extract;
6) Dissolving the apple crude extract in distilled water, stirring to dissolve completely, pre-removing impurities with 0.45 μm organic phase microfiltration membrane, collecting filtrate, ultrafiltering the filtrate with ultrafiltration membrane with molecular cut-off of 2kDa at normal temperature and 0.1MPa to obtain ultrafiltrate, and freeze-drying the ultrafiltrate at-25deg.C for 24-48 hr to obtain apple extract.
The preparation method of the whitening nanoemulsion containing 4-butylresorcinol sequentially comprises the following steps of:
1) Weighing each of the substances according to the components provided in examples 1 to 14;
2) Mixing the weighed organic phases in the step 1), heating to 50 ℃, adding 4-butyl resorcinol, tocopheryl acetate and 3-o-ethyl ascorbic acid, and mixing; adding each component of the emulsifier phase, stirring and dissolving;
3) The remaining components are added to the aqueous phase.
Example 15
The product prepared in the example 9 is added into the emulsion according to the mass ratio of 1:9, and the mixture is uniformly mixed.
Example 16
The product prepared in example 10 is added into the emulsion according to the mass ratio of 1:9, and the mixture is uniformly mixed.
Example 17
The product prepared in example 11 is added into the emulsion according to the mass ratio of 1:9, and the mixture is uniformly mixed.
Comparative example 1
The individual substances and their components are the same as those provided in example 8, except that the hop extract is prepared by conventional aqueous extraction.
10G of hops are taken, 80g of 60wt% ethanol solution is added, after soaking for 1 hour, reflux extraction is carried out for 1 hour under the water bath condition of 80 ℃, the extracting solution is separated and repeated twice, and the two extracting solutions are combined and filtered, thus obtaining the clarified hops extracting solution. And (3) placing the clear solution in a vacuum drying oven, continuously drying at 80 ℃ and under the vacuum degree of-0.05 MPa for 48 hours to obtain a dried product, and crushing to obtain the hop extract powder.
Comparative example 2
The individual substances and their components are the same as those provided in example 8, except that the apple extract is obtained by direct purchase.
In order to prove the effect of the technical scheme provided by the application, experimental data of the technical scheme provided by the application are given below:
test example one: nanoemulsion particle size distribution
The particle size distribution of the nanoemulsions in example 1 and example 8 is detected by a Markov laser particle sizer, and the results are shown in fig. 1 (example 1) and fig. 2 (example 8), so that the nanoemulsions prepared by the method are in normal distribution, the median diameter is 10-18nm, the particle size distribution is uniform, and the PDI is less than 0.1.
Test example two: nanoemulsion placement stability study
Examples 1-14, comparative example 1 were placed at room temperature protected from light, taken out at different time points, tested for macroscopic state and particle size distribution, and characterized for nanoemulsion stability, with the following results:
TABLE 3 nanoemulsion shelf stability results
The nanoemulsion prepared by the invention has good placement stability.
Test example three: structural stability study in nanoemulsion
The structural stability of nanoemulsion after being added into essence is observed by a Transmission Electron Microscope (TEM), and the results are shown in fig. 3 (example 15), fig. 4 (example 16) and fig. 5 (example 17), so that the distribution of nanoemulsion drops of 10-20nm is clearly shown around emulsion essence large-particle-size emulsion drops, and a stable nanostructure is maintained and cannot be damaged due to the addition into the emulsion essence.
Test example four: 4-butyl resorcinol nanoemulsion and solution transdermal test
1.32 ℃ Transdermal test
Experimental conditions: 32 ℃ (according to the requirements of Chinese pharmacopoeia, simulate the skin temperature after warm water skin cleaning)
And (3) comparing products: the product provided in example 1 (designated 4-butylresorcinol nanoemulsion) and 4-butylresorcinol solution (designated solution set).
Dissolution medium: physiological saline
Experimental skin: standard skin after dehairing and degreasing treatment of skin of Kunming mouse
Transdermal test results:
TABLE 4 cumulative 48h transmittance of solution set (%)
Table 5 4-butyl resorcinol nanoemulsion 48h cumulative transmittance (%)
Time (h) | Cumulative permeability 1 | Cumulative permeability 2 | Cumulative permeability 3 | Average cumulative transmittance% | SD |
0.5h | 0.4669 | 0.4706 | 0.4595 | 0.46567 | 0.00565 |
1h | 0.8595 | 0.8646 | 0.8823 | 0.8688 | 0.01197 |
2h | 1.4488 | 1.4617 | 1.4742 | 1.46157 | 0.0127 |
4h | 2.4322 | 2.4388 | 2.4417 | 2.43757 | 0.00487 |
6h | 3.1343 | 3.1376 | 3.141 | 3.13763 | 0.00335 |
8h | 3.8971 | 3.9115 | 3.9078 | 3.90547 | 0.00748 |
10h | 4.7805 | 4.7886 | 4.7883 | 4.7858 | 0.00459 |
12h | 7.9016 | 7.8697 | 7.9428 | 7.9047 | 0.03665 |
24h | 11.4087 | 11.3364 | 11.2699 | 11.33833 | 0.06942 |
48h | 17.0738 | 17.1043 | 17.0672 | 17.08177 | 0.01979 |
Table 6 solution set to 4-butylresorcinol nanoemulsion cumulative transdermal rate comparison
Statistical analysis was performed on 4-butylresorcinol nanoemulsion group (NE) and solution group (solution) data;
0.5h:P=0.00000004101<0.01;
1h:P=0.0000001899<0.01;
2h:P=0.00000082<0.01;
4h:P=0.0000002814<0.01。
After the end of the 48-hour experiment, it was observed that: the skin tissue for the 4-butyl resorcinol nanoemulsion group experiment has no obvious difference from the skin tissue before the experiment in terms of appearance and touch, but after the skin penetration experiment, the central round area contacted by the solution group is obviously yellow, the skin is thinned, the skin is broken when touched lightly, and the skin is seriously damaged, as shown in figure 6.
The transdermal efficiency of the 4-butyl resorcinol nanoemulsion group is obviously higher than that of a solution group within 4 hours, the transdermal efficiency of the solution group is increased from 6 hours later, and the transdermal efficiency is higher than that of the nanoemulsion group, which indicates that the skin is thinned and damaged, and the permeability is obviously enhanced.
And performing t-test analysis of variance on the data of the time point when the accumulated permeability of the nanoemulsion group is higher than that of the solution group, wherein the result shows that the P value is smaller than 0.01 within 4 hours of the test, namely the accumulated permeability of the nanoemulsion group is obviously higher than that of the solution group, and the accumulated permeability of the nanoemulsion group and the solution group have statistical differences.
Transdermal experiments at 2.37 ℃
Experimental conditions: 37 ℃ (simulating skin temperature after hot water cleansing)
And (3) comparing products: the product provided in example 1 (designated 4-butylresorcinol nanoemulsion) and 4-butylresorcinol solution (designated solution set).
Dissolution medium: physiological saline
Experimental skin: standard skin after dehairing and degreasing treatment of skin of Kunming mouse
TABLE 7 cumulative transmittance of 48h for solution set (%)
Table 8 4-butyl resorcinol nanoemulsion 48h cumulative transmittance (%)
Time of | Cumulative permeability 1 | Cumulative permeability 2 | Cumulative permeability 3 | Average cumulative transmittance% | SD |
0.5h | 0.3626 | 0.3549 | 0.3500 | 0.3559 | 0.0064 |
1h | 0.8486 | 0.8525 | 0.8436 | 0.8482 | 0.0045 |
2h | 1.1990 | 1.1931 | 1.2010 | 1.1977 | 0.0041 |
4h | 2.0954 | 2.0962 | 2.0911 | 2.0942 | 0.0028 |
6h | 3.0822 | 3.0588 | 3.0498 | 3.0636 | 0.0167 |
8h | 3.7682 | 3.7637 | 3.7681 | 3.7667 | 0.0025 |
10h | 4.5530 | 4.5485 | 4.5326 | 4.5447 | 0.0107 |
12h | 5.4281 | 5.4166 | 5.4202 | 5.4216 | 0.0059 |
24h | 9.9234 | 9.9227 | 9.8478 | 9.8979 | 0.0435 |
48h | 20.6089 | 20.7437 | 20.7341 | 20.6956 | 0.0752 |
Table 9 solution set comparison of cumulative transdermal rate with 4-butylresorcinol nanoemulsion
Time (h) | Cumulative transdermal rate of 4-butylresorcinol solution% | Accumulated transdermal rate of 4-butyl resorcinol nanoemulsion% |
0.5 | 0.5442±0.0007 | 0.3559±0.0064 |
1 | 1.6124±0.0034 | 0.8482±0.0045 |
2 | 3.9286±0.0167 | 1.1977±0.0041 |
4 | 7.9511±0.0841 | 2.0942±0.0028 |
6 | 13.5432±0.0592 | 3.0636±0.0167 |
8 | 18.5827±0.1012 | 3.7667±0.0025 |
10 | 22.2143±0.0905 | 4.5447±0.0107 |
12 | 25.2030±0.3144 | 5.4216±0.0059 |
24 | 32.2237±0.3357 | 98979±0.0435 |
48 | 36.8139±0.4703 | 20.6956±0.0752 |
As can be seen from the above table, in the transdermal experiments at 37 ℃, the cumulative skin permeation rate of the 4-butylresorcinol solution group from 0.5h is greater than that of the 4-butylresorcinol nanoemulsion group, and the P value is less than 0.05, with significant difference. The difference between the solution group and the nanoemulsion group is not large in the first 2 hours, the difference of the permeability of the 4-butyl resorcinol nanoemulsion and the solution group is gradually increased along with the deepening of the skin damage degree after 2 hours, and the solution group maintains higher skin permeability until the end of the 48-hour experiment. It is presumed that the temperature dependence of 4-butyl resorcinol on skin irritation injury is enhanced with the increase of temperature, and the nanoemulsion can encapsulate 4-butyl resorcinol to form a nanocarrier, and has the functions of slow release and mild delivery into cells. Therefore, after the temperature is increased, the skin of the solution group is obviously damaged within half an hour, the permeability is obviously increased, and the accumulated skin permeability of the solution group is obviously higher than that of the nanoemulsion group.
Comparison of cumulative skin penetration of 4-butylresorcinol solution with nanoemulsions at different temperatures (32 ℃ and s37 ℃) nanoemulsion group 4-butylresorcinol nanoemulsion group (NE) data at 32 ℃ and 37 ℃ were statistically analyzed:
0.5h:P=0.000023622<0.01;
1h:P=0.04934<0.05;
2h:P=0.000004341<0.01;
4h:P=0.00000004675<0.01;
6h:P=0.001675896<0.01;
8h:P=0.000006972<0.01;
10h:P=0.00000362818<0.01;
12h:P=0.0000000333<0.01;
24h:P=0.000006917<0.01;
48h:P=0.0000001428<0.01;
Statistical analysis of data at 32℃and 37℃for the 4-butylresorcinol solution group (solution group):
0.5h:P=0.0000000000095445<0.01;
1h:P=0.00000000009<0.01;
2h:P=0.000000001433<0.01;
4h:P=0.0000000282<0.01;
6h:P=0.00000000337<0.01;
8h:P=0.00000000665<0.0 1;
10h:P=0.0000000012<0.01;
12h:P=0.0000000982<0.0 1;
24h:P=0.000000165<0.01;
48h:P=0.000002941<0.01。
From fig. 8, fig. 9 and data analysis, it is known that the skin permeability of the nanoemulsion group is not increased along with the temperature rise to 37 ℃, but is slightly lower than 32 ℃ instead, and the damage capability of the 4-butylresorcinol to the skin is obviously increased along with the temperature rise only in 48 hours of 37 ℃ groups, so that the nanoemulsion has a wrapping effect on the nanoemulsion, the skin damage is small, the skin state is good in 24 hours, and the skin permeability is obviously increased due to the fact that the 4-butylresorcinol wrapped in the nanoemulsion has a certain damage to the skin at 48 hours. The phenomenon that the damage capability of 4-butyl resorcinol to skin is obviously increased along with the temperature rise is more obvious, 4-butyl resorcinol directly acts on the skin, the skin permeability is higher than 32 ℃ from 0.5h to 48h at 37 ℃, and the difference between the 4-butyl resorcinol and the skin permeability is increased along with the time, so that the skin damage is more serious and the skin permeability is obviously increased.
In combination with the experimental results and data analysis, it can be seen that the 4-butyl resorcinol nanoemulsion group is compared with the solution group: the skin irritation and injury effects of the 4-butylresorcinol are reduced through the encapsulation of the nano-carrier; the skin permeability of the 4-butyl resorcinol nanoemulsion group is obviously higher than that of the solution group within 2 hours (the acting time of the skin care product is met) under the condition of normal skin temperature (32 ℃); increasing the temperature (e.g., 37 ℃) significantly increases the skin damage of 4-butylresorcinol.
Test example five: freckle removing and whitening efficacy test
1 Principle and method
(1) Principle and purpose of testing
The freckle removing and whitening effects of the test object are evaluated by inducing a melanin model generated by melanoma cells and detecting the relative concentration of melanin in the cells.
And evaluating the freckle removing and whitening effects of the test product by detecting the melanin content of the test sample in the cell model as an index.
(2) Evaluation index and determination criterion
Table 10 evaluation index and judgment Standard
(3) Test subjects
Positive control: 0.05% vitamin C
Sample: examples 1-14, comparative examples 1-2;
(4) Instrument reagent
Enzyme-labeled instrument (BioTek), analytical balance (Shimadzu), pipette (Beijing Dalong)
Cell line: melanoma cells (B16)
Culture solution: DMEM medium (sameifer) experimental kit containing 10% fbs (Shanghai dashi biotechnology): CCK-8 kit (Solarbio), melanin kit (Xinquan technology)
5. Environmental conditions and culture conditions
Environmental conditions: the temperature is 18-27 ℃, and the humidity is 30-70% RH
Culture conditions: culturing at 37deg.C under 5% CO 2 and saturated humidity
6. Test method
6.1 Cell Activity test
1. Cell suspensions (100. Mu.L/well) were seeded in 96-well plates. The plates were placed in an incubator for preculture.
2. 10 Mu LCCK-8 solutions were added to each well.
3. The plates were incubated in the incubator for 2 hours.
4 Absorbance at 450nm was measured with a microplate reader.
6.2 Melanin content determination
1. Melanoma cells are inoculated into a 96-well plate and cultured for 18-24 hours.
2. The blank groups were replaced with maintenance medium and the remaining groups were incubated with maintenance medium containing sample or positive control for 48h.3. The original medium was discarded and washed 3 times with PBS
4. Adding DMEM medium (except blank group), inducing for 48 hr, and making cells produce melanin
5. Cell supernatants were collected and assayed for melanin content according to kit instructions.
6. Data analysis:
data were analyzed using SPSS and expressed as mean ± standard deviation.
1. Cell activity relative to each group was calculated with the cell activity of the control group being 100%.
Relative cell activity (%) = [ (OD sample-OD blank)/(OD control-OD blank) ] ×100%
2. Melanin downregulation.
Down-regulation (%) = (1-T/C) ×100%
Wherein:
Mean value of melanin content of T-test object;
C-blank/solvent control melanin content average.
2. Test results
1. Cell activity analysis of the product provided in example 8, table 11
TABLE 11 analysis of cell Activity
2. Product fine melanin downregulation assay provided in example 8
TABLE 12 Effect of test substances on cellular melanin levels
Group of | Down regulation (%) | P value |
Blank control group | / | / |
Sample (0.05 mg/mL) | 31.28±1.24 | <0.001 |
Sample (0.025 mg/mL) | 20.06±2.23 | <0.001 |
Sample (0.0125 mg/mL) | 14.53±1.54 | <0.001 |
Positive control group | 35.23±1.68 | <0.001 |
3. The cell activities of the products provided in comparative examples 1-2, examples 3, examples 6, examples 8, examples 10 and examples 13 were measured using a sample concentration of 0.025mg/mL, and the cell melanin level downregulation (%), table 13.
TABLE 13
Cell relative Activity (%) | Down regulation (%) | P value | |
Example 1 | 99.00±1.78 | 16.02±2.47 | <0.001 |
Example 3 | 99.00±1.91 | 15.45±2.06 | <0.001 |
Example 6 | 99.00±1.89 | 14.27±1.97 | <0.001 |
Example 8 | 99.00±1.65 | 20.06±2.23 | <0.001 |
Example 10 | 99.00±1.78 | 17.05±2.09 | <0.001 |
Example 13 | 99.00±2.05 | 16.08±1.79 | <0.001 |
Comparative example 1 | 99.00±1.79 | 17.02±1.75 | <0.001 |
Comparative example 2 | 99.00±1.68 | 16.96±2.12 | <0.001 |
Remarks: p > 0.05, representing no statistical difference between the two sets of data; 0.01< P < 0.05 means statistically significant; 0.001 < P < 0.01 indicates significant differences; p < 0.001, which indicates a significant difference.
According to the test results, the positive control group showed significantly reduced relative melanin content (P < 0.05) compared with the blank group, and the test results were valid. The concentrations of the samples are respectively 0.05mg/mL, 0.025mg/mL and 0.0125mg/mL, the relative content of melanin can be reduced, and the samples have obvious differences (P is less than 0.05), so that the samples have the effects of removing freckles and whitening; the increase of the content of the 4-butyl resorcinol is beneficial to improving the whitening effect of the product; in addition, the 4-butyl resorcinol compound costustoot extract, the hop extract and the apple extract further improve the whitening effect of the product; as can be seen from comparative examples 1,2 and 8, the hop extract and apple extract prepared by the extraction method provided by the present application have significantly higher whitening effect than the hop extract and apple extract provided in comparative examples 1 and 2 and other components in the formula, probably due to higher activity of the hop extract and apple extract provided by the present application.
Claims (9)
1. The whitening nanoemulsion containing 4-butylresorcinol is characterized by comprising the following components in percentage by mass: 13.08 to 29.12 percent of active factor, 4 to 40.5 percent of emulsifier phase, 2.2 to 41.8 percent of organic phase, 0.1 to 1 percent of preservative and a proper amount of water;
the active factors comprise 4-butylresorcinol, nonapeptide-1, decarboxylated carnosine hydrochloride, 3-o-ethyl ascorbic acid, tocopheryl acetate, radix aucklandiae extract, hops extract, and apple extract;
The emulsifier comprises poloxamer, polyvinylpyrrolidone and cetostearyl alcohol polyether-20;
The mass ratio of the 4-butylresorcinol to the nonapeptide-1 to the decarboxylated carnosine hydrochloride to the 3-o-ethyl ascorbic acid to the tocopheryl acetate to the costustoot extract to the hop extract to the apple extract is 4-8:0.08-0.12:4-8:4-8:1-5:2-3:1-2:3-5.
2. The whitening nanoemulsion comprising 4-butylresorcinol of claim 1, wherein said emulsifier further comprises at least one of cetostearyl alcohol polyether-20, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, acrylates/C10-30 alkanol acrylate cross-linked polymer.
3. The whitening nanoemulsion containing 4-butylresorcinol according to claim 1, wherein the mass ratio of poloxamer, cetostearyl alcohol polyether-20 and polyvinylpyrrolidone is 1-10:1-10:2-3.
4. The whitening nanoemulsion containing 4-butylresorcinol according to claim 1, wherein the organic phase consists of isopropyl palmitate, 1, 2-hexanediol, 1, 2-pentanediol and ethoxydiglycol in a mass ratio of 1-10:1-1.
5. The 4-butylresorcinol-containing whitening nanoemulsion of claim 1, wherein the elecampane extract is prepared by the following method: pulverizing radix aucklandiae decoction pieces to below 100 meshes, adding 3-5 equivalents of 50% -80% ethanol solution, performing ultrasonic extraction at 20-35 ℃ for 0.5-1 h, removing an alcohol phase by rotary evaporation of an extract liquid, filtering by a microporous filter membrane, and freeze-drying to obtain an extract.
6. The 4-butylresorcinol-containing whitening nanoemulsion of claim 1, wherein the hops extract is prepared by the following method:
(1) Collecting hops, naturally drying, crushing, and sieving with a 20-40 mesh sieve to obtain beer pollen;
(2) Adding ethanol with the mass concentration of 50-70% into beer pollen according to the volume ratio of 6-8:1, soaking the beer pollen for 30-50 minutes, performing ultrasonic extraction for 15-30 minutes at the frequency of 40-60 kHz and the power of 150-300W at the temperature of 40-55 ℃, and filtering the extracting solution;
(3) Adding ethanol solution with the mass concentration of 50-70% into filter residues again according to the volume ratio of ethanol to beer pollen of 3-5:1, and performing ultrasonic extraction for 10-20 min at the frequency of 40-60 kHz and the power of 150-300W at the temperature of 40-50 ℃; filtering to obtain a second extracting solution, combining the extracting solutions, evaporating and concentrating at the temperature of between 30 and 50kPa and between 35 and 45 ℃ to recover ethanol to obtain an extract primary extract;
(4) Dissolving the extract in an aqueous solution with the mass concentration of 2t% of ethanol, carrying out component enrichment and separation by adopting AB-8 type macroporous adsorption resin, eluting with 20% of ethanol, and then eluting with 70% of ethanol;
(5) Collecting 70% ethanol eluate, and concentrating under reduced pressure of 30kPa to obtain 70% ethanol-eluted flos Lupuli extract;
(6) Eluting the hop extract with 70% ethanol at-50deg.C to-30deg.C for 18-20 hr to obtain hop extract.
7. The whitening nanoemulsion comprising 4-butylresorcinol according to claim 1, wherein the apple extract is prepared by the following method:
1) Selecting fresh apples, cleaning, removing seeds, and crushing the apples to obtain apple paste;
2) Adding 0.1-0.25% of cellulase and 0.2-0.5% of pectase into the apple paste according to the mass of the apple paste, adding 50wt% of ethanol which is 20 times of the mass of the apple paste, adding citric acid to adjust the PH to 5.5-6.0, carrying out enzymolysis for 1-2 h at 50-60 ℃, and then inactivating enzyme in boiling water for 20-30 min;
3) Placing the substances after enzyme deactivation into an ultrasonic extractor, performing ultrasonic treatment at 600W and 50-55 ℃ for 15-20 min, centrifuging at 5000rpm for 12-20 min, centrifuging the extracting solution, and collecting supernatant;
4) Adding 50wt% ethanol with 20 times of the volume of the filter residue into the filter residue, placing into an ultrasonic extractor, performing ultrasonic treatment at 600W and 50-55 ℃ for 15-20 min, centrifuging at 4000rpm for 12-20 min, centrifuging the extracting solution, and collecting supernatant;
5) Combining the supernatant collected in the step 4) and the step 5), concentrating the supernatant in a vacuum rotary evaporator for 1-2 hours until no liquid is evaporated, and freeze-drying the concentrated supernatant at 20Kpa and-25 ℃ for 24-48 hours to obtain an apple crude extract;
6) Dissolving the apple crude extract in distilled water, stirring to dissolve completely, pre-removing impurities with 0.45 μm organic phase microfiltration membrane, collecting filtrate, ultrafiltering the filtrate with ultrafiltration membrane with molecular cut-off of 2kDa at normal temperature and 0.1MPa to obtain ultrafiltrate, and freeze-drying the ultrafiltrate at-25deg.C for 24-48 hr to obtain apple extract.
8. The method for preparing the whitening nanoemulsion containing 4-butylresorcinol according to claim 1, which is characterized by comprising the following steps in sequence:
1) Weighing each substance according to the mass fraction of any one of claims 1 to 4;
2) Mixing the organic phases weighed in the step 1), heating to 50 ℃, and then adding 4-butylresorcinol, tocopheryl acetate and 3-o-ethyl ascorbic acid, and mixing; adding each component of the emulsifier phase, stirring and dissolving;
3) And adding the rest components into the water phase for dissolution, heating the water phase to 50 ℃ after dissolution, slowly adding the organic phase while stirring at the maintained temperature, and stirring until the organic phase is uniform and transparent.
9. Use of the 4-butylresorcinol-containing whitening nanoemulsion of claim 1 as an additive for cosmetics.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311871201.4A CN117797040B (en) | 2023-12-29 | 2023-12-29 | Whitening nanoemulsion containing 4-butylresorcinol and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311871201.4A CN117797040B (en) | 2023-12-29 | 2023-12-29 | Whitening nanoemulsion containing 4-butylresorcinol and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117797040A CN117797040A (en) | 2024-04-02 |
CN117797040B true CN117797040B (en) | 2024-06-04 |
Family
ID=90425250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311871201.4A Active CN117797040B (en) | 2023-12-29 | 2023-12-29 | Whitening nanoemulsion containing 4-butylresorcinol and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117797040B (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170004631A (en) * | 2015-07-03 | 2017-01-11 | 김혜정 | A cosmetic composition for anti-wrinkle and skin whitening effect |
CN111658585A (en) * | 2020-06-24 | 2020-09-15 | 珠海美逸生物科技有限公司 | Whitening and spot-fading composition and preparation method thereof |
CN112618431A (en) * | 2020-12-24 | 2021-04-09 | 广州尚品生物科技有限公司 | Novel whitening composition, preparation method and application |
CN114931517A (en) * | 2022-06-07 | 2022-08-23 | 欧诗漫生物股份有限公司 | Whitening body and preparation method and application thereof |
CN115919676A (en) * | 2023-03-11 | 2023-04-07 | 广州华厦生物制药有限公司 | Whitening and freckle-removing porcelain cream for cleaning face |
CN116617097A (en) * | 2023-07-13 | 2023-08-22 | 天津科技大学 | Whitening 4-butyl resorcinol gel bead and preparation method thereof |
CN116763702A (en) * | 2022-03-10 | 2023-09-19 | 泉后(广州)生物科技研究院有限公司 | Composition for fading deep spots as well as preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11071701B2 (en) * | 2016-06-30 | 2021-07-27 | Symrise Ag | Medicament and cosmetic composition comprising resorcinol derivatives |
-
2023
- 2023-12-29 CN CN202311871201.4A patent/CN117797040B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170004631A (en) * | 2015-07-03 | 2017-01-11 | 김혜정 | A cosmetic composition for anti-wrinkle and skin whitening effect |
CN111658585A (en) * | 2020-06-24 | 2020-09-15 | 珠海美逸生物科技有限公司 | Whitening and spot-fading composition and preparation method thereof |
CN112618431A (en) * | 2020-12-24 | 2021-04-09 | 广州尚品生物科技有限公司 | Novel whitening composition, preparation method and application |
CN116763702A (en) * | 2022-03-10 | 2023-09-19 | 泉后(广州)生物科技研究院有限公司 | Composition for fading deep spots as well as preparation method and application thereof |
CN114931517A (en) * | 2022-06-07 | 2022-08-23 | 欧诗漫生物股份有限公司 | Whitening body and preparation method and application thereof |
CN115919676A (en) * | 2023-03-11 | 2023-04-07 | 广州华厦生物制药有限公司 | Whitening and freckle-removing porcelain cream for cleaning face |
CN116617097A (en) * | 2023-07-13 | 2023-08-22 | 天津科技大学 | Whitening 4-butyl resorcinol gel bead and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
王建新.化妆品植物原料大全.中国纺织出版社,2012,(第第1版版),第291-294,360-361页. * |
Also Published As
Publication number | Publication date |
---|---|
CN117797040A (en) | 2024-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2574332A1 (en) | MC-1 R, MC-2 R, and µ opioid receptors modulation | |
KR102171133B1 (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
KR20100135871A (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
JP7174736B2 (en) | Fermented extract of the aerial part of bitter orange | |
CN110755328A (en) | Beautifying, moisturizing and repairing composition and application thereof | |
KR20160125784A (en) | Shiunko fermented oil and producing method thereof | |
CN110772444A (en) | Skin conditioner and mask for whitening and removing wrinkles and preparation method thereof | |
KR20220122452A (en) | Method for manufacturing microalgae extract and cosmetic composition for wrinkle improvement using peptide complex obtained from microalgae extract | |
CN104490713A (en) | Super-soft living spring skin care product with functions of removing foul, tightening, resisting wrinkles and activating skin | |
KR20190063549A (en) | Cosmetic Composition Comprising Bamboo Fermented Extract | |
KR101563322B1 (en) | manufacturing method of neck patch therof | |
CN112386547B (en) | Skin health care application of pineapple extract | |
CN107802545A (en) | A kind of anti-oxidant and lightening compositions and the skin care item containing said composition | |
CN111870541A (en) | Herbal whitening compound composition, mask and preparation method thereof | |
CN117797040B (en) | Whitening nanoemulsion containing 4-butylresorcinol and preparation method thereof | |
KR20140130277A (en) | Composition of skin external application comprising glycoprotein | |
KR20120043254A (en) | Cosmetic pack composition containing jeju scoria powder | |
CN111920703B (en) | Hyaluronic acid-containing composition for skin care and application thereof | |
CN107753378A (en) | A kind of extracts of Chinese herbal medicine and its preparation method and application | |
KR102253894B1 (en) | Skin regeneration, skin moisturizing and skin whitening composition containing diatomaceous earth | |
KR20220070122A (en) | A composition for skin anti-pollution containing a daughter-in-law navel extract | |
CN109602666B (en) | Whitening composition containing lime fruit extract | |
AU2017425084B2 (en) | Topical herbal compositions | |
KR20210094312A (en) | Cosmetic composition for enhancing skin barrier function and manufacturing method thereof | |
KR102515074B1 (en) | Cosmetic composition comprising fermented producrt of Perilla frutescens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |